Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Evgen Pharma: Johns Hopkins research further assesses the potential of company's drug to treat COVID-19
Scientists found that sulforaphane, the active ingredient in the company’s multi-purpose treatment, SFX-01, prevents virus-induced cell death sparked by variants of the SARS-CoV-2 virus and another unnamed coronavirus
Work carried out by researchers at the world-famous Johns Hopkins in the US appears to underline the potential of Evgen Pharma PLC’s (LON:EVG) lead drug in battling Coronavirus (COVID-19).
Researchers found that sulforaphane, the active ingredient in the company’s multi-purpose treatment, SFX-01, prevents virus-induced cell death sparked by variants of the SARS-CoV-2 virus and another unnamed Coronavirus.
In addition, the Johns Hopkins team went on to demonstrate the drug inhibited toxicity to cells as a pre-treatment before inoculation while also acting “synergistically” with antiviral drug remdesivir.
Results from the lab-based work formed the basis of a recent pre-print publication that was released before it was peer-reviewed “given the urgency of the current pandemic”.
SFX-01 is being administered to treat people with severe COVID in the STAR clinical trial being carried out by scientists at Dundee University.
An interim analysis of the first hundred patients in the STAR study is expected sometime this quarter.
Of the Johns Hopkins update, Evgen chief executive, Huw Jones, said: “If the data continue to demonstrate efficacy after peer review, they underpin and support the hypothesis we are testing with the University of Dundee in the STAR COVID-19 clinical study.”
The new drive aims to find drugs that work against the virus – and its variants – in the early stages of disease. Most of the drugs discovered so far have been for use by people severely ill in hospital.
The prime minister and health secretary both referenced the vaccines taskforce in the announcement of the new body. “The success of our vaccination programme has demonstrated what the UK can achieve when we bring together our brightest minds,” said Johnson.
“Our new antivirals taskforce will seek to develop innovative treatments you can take at home to stop Covid-19 in its tracks. These could provide another vital defence against any future increase in infections and save more lives.”
The health secretary, Matt Han****, said he was “committed to boosting the UK’s position as a life science superpower and this new taskforce will help us beat Covid-19 and build back better”.
He lost out on some £12M by dumping SNG a few months before trial results.
Hopefully he'll have a similar outcome here.
i agree, but Griffiths has made millions from investing so he must be a shrewd operator , surrounded by a good team.
The Government’s chief scientific adviser Sir Patrick Vallance said: “The speed at which vaccines and therapeutics such as dexamethasone have been identified and deployed against Covid-19 has been critical to the pandemic response.
“Antivirals in tablet form are another key tool for the response.
“They could help protect those not protected by or ineligible for vaccines.
“They could also be another layer of defence in the face of new variants of concern.”
Dr Nikita Kanani, medical director of primary care for NHS England said: “The NHS has put research into reality at record speed during the pandemic and this taskforce will now help us to identify and roll out even more new, convenient treatments for patients with Covid-19.”
Commenting on the announcement, Dr Penny Ward, visiting professor in pharmaceutical medicine at Kings College London, said: “Antiviral treatment of influenza has been shown to reduce hospitalisation and prevent death in epidemic and pandemic waves and a similar, preferably simple to use antiviral, suitable for use in the community can add to the range of interventions critical to enable us to remain on top of the Covid pandemic even in the event of the emergence of viral variants insensitive to vaccines.”
She said that there are a number of early phase trials looking at oral antiviral medications.
I can tell you for certain that Mr Griffiths does not have a magic crystal ball that can foresee clinical trial results
https://www.investegate.co.uk/synairgen-plc--sng-/rns/holding-s--in-company/202004011656114853I/
Fascinating.. if it were true that SFX-01 is effective. I think Mr Richard Griffins would be kicking himself for selling.
What else can it be that could be ready by Autumn, apart from SFX-01, where efficacy results are expected imminently on the back of and John Hopkins University stunning research on Sulforaphane???? Gla Holders ;-)
A PILL to kill third wave: Boris Johnson launches 'ambitious' new 'antivirals taskforce' so Britons can take tablets for Covid at home 'by autumn'
Government is launching an 'antivirals taskforce' to find two drugs by autumn for people to take at home
They will be pills to take at home before serious Covid develops, officials say, reducing need for hospital beds
Government staff, university scientists and pharmaceutical company experts will be on panel
Most will be vaccinated by that time but drugs will help control local outbreaks and squash spikes in cases
httTps://www.dailymail.co.uk/news/article-9491869/Coronavirus-Britain-pills-treat-Covid-autumn.html
Doesn't appear to be much stock available online